摘要
目的:观察复方苦参结肠溶胶囊对溃疡性结肠炎(UC)患者的治疗作用以及对结肠黏膜IκB-α蛋白的表达作用,并探讨其作用机制.方法:经结肠镜及病理证实的UC患者24例,随机分为复方苦参组和美沙拉嗪组,复方苦参组16例用复方苦参结肠溶治疗,美沙拉嗪组8例用美沙拉嗪治疗,共治疗8wk.采用免疫组织化学法检测患者治疗前后IκB-α蛋白的阳性细胞表达率.结果:复方苦参组总有效率为93.75%,美沙拉嗪组为87.50%,2组差异无统计学意义(P>0.05).复方苦参组和美沙拉嗪组治疗前结肠黏膜IκB-α蛋白阳性细胞表达率明显高于治疗后(25.6%±2.9%vs21.5%±4.9%,23.5%±5.6%vs21.8%±5.0%,均P<0.01),治疗后复方苦参组结肠黏膜IκB-α蛋白阳性细胞表达率与美沙拉嗪组无明显统计学意义(P>0.05).结论:复方苦参结肠溶胶囊对UC患者具有较好的治疗作用,治疗后患者结肠黏膜IκB-α蛋白阳性细胞表达率明显降低,这可能是其作用机制之一.
AIM：To investigate the therapeutic effects of colonic-coated compound lightyellow sophora root capsules（CCLSRC）in patients with ulcerative colitis（UC）and explore the mechanisms underlying such effects. METHODS：Twenty-four patients diagnosed with ulcerative colitis by colonoscopy and biop-sy were randomly divided into two groups：Chinese medicine treatment（CMT）group（n=16） and Western medicine treatment（WMT）group （n=8）.Patients in the CMT group were treated with CCLSRC for eight weeks,while those in the WMT group were treated with mesalazine for the same duration.The positive expression rates of IκB-αin colonic mucosa in all patients were examined by immunohistochemistry before and after treatment. RESULTS：The total response rates achieved in the CMT group and WMT group were 93.75% and 87.50%,respectively,with no significant difference between the two groups（P〉0.05）. The positive expression rate of IκB-αwas higher in pretreated patients than in post-treated ones （25.6%±2.9%vs 21.5%±4.9%,23.5%±5.6%vs 21.8%±5.0%,both P〈0.01）.After treatment,no significant difference was observed in the positive expression rate of IκB-αbetween the two groups（P〉0.05）. CONCLUSION：CCLSRC exerts good curative effects against UC perhaps through inhibition of IκB-αexpression in colonic mucosa.
出处
《世界华人消化杂志》
CAS
北大核心
2009年第23期2429-2432,共4页
World Chinese Journal of Digestology
基金
国家自然科学基金资助项目
No30772878~~
关键词
复方苦参结肠溶
美沙拉嗪
溃疡性结肠炎
核转录因子ΚB
Colonic-coated Compound Lightyellow Sophora Root Capsule Mesalazine Ulcerative colitis Nuclear transcription factor-kappa B
